Key facts
- It has raised $1.0M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include gBETA, Serra Ventures, Symbiotic Ventures, BrightStar Wisconsin Foundation, Central Texas Angel Network.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for SpayVac
- ·The full record, as it builds
Funding rounds
No funding rounds for SpayVac are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SpayVac
Developer of an immunocontraception vaccine designed to create fertility-control vaccines for overabundant wildlife. The company's drug release technology offers a portfolio of vaccines for the population control of animals such as feral cats, stray/feral dog, feral cattle, kangaroos, wild hogs, antelope, wild burros, and feral camels, enabling clients to conserve invasive animal species.
- Sector
- Materials and Resources
- HQ
- Madison, WI, United States
- Founded
- 2017
- Employees
- 3
- Website
- spayvac.com/
- Ownership
- Privately Held (backing)
SpayVac doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SpayVac shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SpayVac in its N-PORT filings yet. We sweep new filings monthly.